€3 million investment into small molecules for muscle regeneration

Written by Freya Leask

Anagenesis Biotechnologies has received a €3 million investment by the Boehringer Ingelheim Venture Fund and Cap Innov’Est.

New investment from the Boehringer Ingelheim Venture Fund (BIVF; Germany) will develop a pluripotent cell-based screening platform for the discovery of small molecules that stimulate muscle regeneration. Anagenesis Biotechnologies’ (France) proprietary Paraxial Mesoderm Multipotent Cells (P2MCs) technology enables the reproducible differentiation of cells in tissues that can give rise to skeletal muscle, tendons and cartilage, amongst others, which are then used to screen small molecule candidates.

Ilka Wicke, Investment Manager at BIVF, said “Anagenesis has a truly different approach to find a solution for muscle regeneration based on its groundbreaking science. This technology could address an important unmet need for patients suffering from genetically based muscle diseases. We are very pleased to support Anagenesis and to collaborate with their highly knowledgeable team.”

Read the full story, originally published on RxNet, the home of pharma R&D>>